Susanne HUCH, PhD
LILIT NERSISYAN, PHD
VICENT PELECHANO, PHD
We are a life science-start-up that set out as a spin-off from SciLifeLab/Karolinska Institutet. Based on our work on microbial metadegradomics we aim to increase efficiency, safety and speed in the development of small molecules modulating the microbiome. Our technology provides immediate information of the effect of new drug substances on the microbiome.
Currently, our team focus on the application of this technology to measure cellular growth at the molecular level and to speed up the diagnosis of phenotypic antimicrobial resistance .
The rapid emergence of antibiotic-resistant bacteria and multidrug-resistant pathogenic fungi pose a threat to global health. If no urgent actions are taken, by 2050, antimicrobial resistance (AMR) will cause an estimated loss of 10 million lives and $US100 trillion. Fast and accurate diagnosis of antimicrobial resistant strains is key to contain the rise of AMR, limit its spread and provide adequate treatment to patients.
We have discovered that by studying how bacterial cells recycle the mRNAs encoding for proteins, we can obtain direct information regarding protein synthesis and cell growths. Our team is leveraging those RNA degradation signatures to obtain fast information regarding specie-specific response to drugs and antibiotic treatments. Importantly, all that can be done in complex microbial samples without the need for cell culture, bacteria isolation or any complex experimental procedures. Our team is is leveraging the use of RNA degradation signatures to provide fast and accurate information of bacterial growth at molecular level.
Huch, S., Nersisyan, L. et al. Atlas of mRNA translation and decay for bacteria. Nat Microbiol (2023). https://doi.org/10.1038/s41564-023-01393-z